Physiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in its innovative obese NASH hamster model on April 28th-30th, 2022 at the International Conference on Fatty Liver in Vienna, Austria.
Meet Dr François Briand, our Director of Research and Development at each break / poster viewing session during the 2-day conference.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.